Webcast - Advances in Gastrointestinal (GI) Cancers

This enduring educational activity titled - "Advances in Gastrointestinal (GI) Cancers: A Virtual International Conference" is an accredited continuing education activity featuring recorded lectures from our virtual conference of the same name held on 3/28/2021.

This educational activity brings together the leading experts in gastro intestinal cancer to discuss recent advances in the field of GI oncology with a focus on biomarker-driven therapies, immuno-oncology, and clinical applications of the recent advances across various GI tumor types. Through these recorded videos, participants will have an opportunity to hear from the leading national and international experts on how recently published data would change practice, some of which will have immediate clinical applications. Furthermore, each session features multiple segments on novel emerging treatment paradigms likely to transform the care of GI cancers in the near future.

This self-paced enduring educational activity is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:

  • Emerging role of immunotherapy in the field of GI cancers
  • Evolving role of circulating tumor DNA (ctDNA) in the management of colorectal cancer
  • Novel emerging therapies for pancreatic cancer
  • Novel treatment options for rectal cancer, including non-operative protocol 
  • Trends, challenges, and controversies in the management of GI cancers

REGISTRATION FEES: 

Registration is free for healthcare providers who are NOT employees of ACCME defined ineligible companies.

If you are a healthcare provider involved in patient care and are not an employee of an ineligible company, please proceed to registration and select "non-industry learner" and your fee will reset to $0.00.

An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients. If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this course.

Target Audience

  • Oncologists
  • Residents/Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Discuss the role of immunotherapy in various GI cancers
  • Review the role of novel biomarkers directing the therapy of GI cancers.
  • Compare and contrast the safety and efficacy of competing therapeutic strategies  influencing the management of GI cancers
  • Describe the application of emerging data into the treatment strategies of GI cancers
  • Identify the areas where precision medicine driven therapy personalizations play an essential role.
Course summary
Available credit: 
  • 3.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 3.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.
Course opens: 
04/06/2021
Course expires: 
03/27/2022
Cost:
$1.00

This educational activity features recorded videos from the live virtual meeting held on 3/28/21. The videos are placed in the following order. Feel free to view the content that is relevant to you. Participants should claim continuing education credits to the extent of their participation.

Session 1: Gastroesophageal cancer

- Gastroesophageal cancer: Recent advances - Dr. Daniel Catenacci (25 minutes)

- Straight talk: Should induction chemotherapy be used before concurrent chemoradiation in the treatment of locally advanced gastroesophageal junction carcinoma? - Dr. Joseph Cho (15 minutes)

Session 2: Hepatobiliary Cancer

- Hepatobiliary cancer: Recent advances - Dr. Ghassan Abou-Alfa (25 minutes)

- Straight talk: Should all patients with advanced biliary tract cancer get genomic study at the time of diagnosis? - Dr. Bhawna Sirohi (15 minutes)

- Straight talk: Role of neoadjuvant chemotherapy in resectable biliary tract cancer - Dr. Rachna Shroff (15 minutes)

Session 3: Pancreatic Cancer & Neuroendocrine Tumor (NET)

- Pancreatic cancer: Recent advances - Dr. Elaine O'Reilly (25 minutes)

- Straight talk: Immunotherapy in pancreatic cancer- ready for prime time? - Dr. Andrew Coveler (15 minutes)

- Straight talk: Which patients with NET should get PRRT and when? - Dr. Aman Chauhan (15 minutes)

Session 4: Colorectal cancer

- Colorectal cancer: Recent advances - Dr. Axel Grothey (25 minutes)

- Straight talk: Watch and Wait for Rectal Cancer: Why, Who, and How? - Dr. Sakti Chakrabarti (15 minutes)

- Straight talk: How I use ctDNA in patients with early-stage colon cancer - Dr. Aparna Parikh (15 minutes)

 

APARNA R. PARIKH, MD

Assistant Professor of Medicine

Harvard Medical School

Learn More

RACHNA T. SHROFF, MD, MS

Associate Professor of Medicine 

The University of Arizona

Learn More

EILEEN O'REILLY, MD

Professor of Medicine

Memorial Sloan Kettering Cancer Center & Cornell University

Learn More

SAKTI CHAKRABARTI, MD

Associate Professor of Medicine

Medical College of Wisconsin

Learn More

GHASSAN ABOU-ALFA, MD

Professor of Medicine

Memorial Sloan Kettering Cancer Center & Cornell University

Learn More

JOSEPH CHAO, MD

Assistant Clinical Professor

City of Hope

Learn More

ANDREW COVELER, MD

Associate Professor of Medicine

University of Washington

Learn More

AXEL GROTHEY, MD

Medical Oncologist/Hematologist

West Cancer Center

Learn More

DANIEL CATENACCI, MD

Associate Professor of Medicine

University of Chicago

Learn More

AMAN CHAUHAN, MD

Assistant Professor of Medicine

University of Kentucky

Learn More

BHAWNA SIROHI, MD

Medical Oncologist

Max Healthcare, New Delhi, India 

Learn More

  

Disclosure of Conflict of Interest:

No individuals in control fo this activity's contents have any relevant financial relationship with an ineligible entity with the exception of the following faculties:

● Dr. Arpana Parikh: Ad Board/Research Funding to Institution -Pfizer, Eli Lilly, Natera, Checkmate, CVS, PMV Pharma, Array, BMS, Guardant, and Novartis.

● Dr. Eileen O’Reilly: Consultant- Celgene-BMS (Spouse), Sobi, Molecular Templates, Boehringer Igelheim, Ipsen, Polaris, Merck, Bayer (Spouse, Eisai (Spouse). Research support/Grant - Genentech-Roche, Celgene-BMS, BioNTech, AstraZenica, Arcus. Other (DSMB) - CytomX Therapeutics, Rafael Therapeutics.

● Dr. Ghassan Abou-Alfa: Research Support/Grant - ActaBiologica, Agios, AstraZeneca, Bayer, Beigene, Berry Genomics, BMS, Casi, Celgene, Exelixis, Genentech/Roche, Halozyme, Incyte, Mabvax, Puma, QED, Sillajen, Yiviva. Consultant - Agios, Astra Zeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Debio, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Gilead, Helio, Incyte, Ipsen, Loxo, Merck, MINA, Polaris, QED, Redhill, Silenseed, Sillajen, Sobi, Therabionics, Twoxar, Vector, Yiviva.

● Dr. Daniel Catenacci: Consultant - Genentech/Roche, Amgen, and honoraria from Genentech/Roche, Amgen, Eli Lilly, Five Prime, Merck, BMS, Taiho, Astellas, Gritstone, Pieris, Daiichi Sankyo, Zymeworks, QED, Foundation Medicine, Tempus, Guardant Health, Archer & Natera.

● Dr. Aman Chauhan - Research Support/Grant - BMS, Clovis, TerSera, Lexicon, Nanopharmeceuticals, EMD Serono. Consultant - Novartis, Ipsen, TerSera, Lexicon.

● Dr. Joseph Chao - Grant/Research Support - Merck. Consultant - Merck, Macrogenics, Foundation Medicine.

● Dr. Andrew Coveler - Grant/Research Support - Medimmune, Seattle Genetics, Amgen Nucana, Abgenomics, Halozyme, Novocure.

● Dr. Axel Grothey - Grant/Research Support - Genentech/Roche, Bayer, Array/Pfizer, Boston Biomedicals, Daiichi. Consultant - Genentech/Roche, Bayer, Array/Pfizer, Daichi Sankyo.

● Dr. Sakti Chakrabarti - Consultant - HalioDx, QED Therapeutics, DAVA Oncology, BioMedical Insights, Inc. Grant/Research Support - MERCK, Taiho Pharmaceutical, Natera, Roche

Important Information about Claiming CME for this activity:

If you participated in our live webinar on 3/28/2021 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 3/28/2021. 


The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.

ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 3.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 3.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.

Price

Cost:
$1.00
Please login or register to take this course.

Registration Fees:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, please register for the course here

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant. Sign up for this activity as an industry representative here. If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.

 

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

 

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you have started watching the recorded content.